News Formal

Wells Fargo becomes bullish on this biotech company

  • 📰 CNBC
  • ⏱ Reading Time:
  • 23 sec. here
  • 10 min. at publisher
  • 📊 Quality Score:
  • News: 40%
  • Publisher: 72%

Health Care Industry Notizia

Neurocrine Biosciences Inc,Wells Fargo & Co,Stock Markets

Wells Fargo believes the company's hyperplasia and depression treatments could each become over $1 billion opportunities.

Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Analyst Mohit Bansal upgraded shares to overweight from equal weight, and raised his price target to $170 from $140, suggesting around 21% upside potential from Tuesday's close. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.

"We think Crinecerfont is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Elsewhere in the company's pipeline, Neurocrine's depression drug NBI-1065845, developed in conjunction with Japanese pharmaceutical company Takeda, showed positive results during a phase II trial. Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opoprtunity.

 

Grazie per il tuo commento. Il tuo commento verrà pubblicato dopo essere stato esaminato.
Abbiamo riassunto questa notizia in modo che tu possa leggerla velocemente. Se sei interessato alla notizia puoi leggere il testo completo qui. Leggi di più:

 /  🏆 12. in İT

Italia Ultime Notizie, Italia Notizie

Similar News:Puoi anche leggere notizie simili a questa che abbiamo raccolto da altre fonti di notizie.

S&P 500 target raised to 5500+ at Wells Fargo on strong earnings growthS&P 500 target raised to 5500+ at Wells Fargo on strong earnings growth
Fonte: Investingcom - 🏆 450. / 53 Leggi di più »